FindTrial
Sign In

To study the clinical variations and dose volume changes with adaptive radiotherapy in head and neck cancers

A prospective study to evaluate the clinical outcomes and dose volume histogram (DVH) parameters of adaptive intensity modulated radiotherapy in the treatment of patients with head and neck cancers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/036417
Enrollment
64
Registered
2021-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

None listed

Sponsors

svims tirupati
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. histopathologically proven squamous cell carcinoma of head and neck 2.cancers of oralcavity, oropharynx, hypopharynx and larynx 3. stage 3 to stage 4b disease 4. patients with ECOG performance status 0 to 2 5. patients who has given approved informed consent

Exclusion criteria

Exclusion criteria: 1. patients previously treated with surgery, chemotherapy or radiotherapy 2. patients with distant metastasis 3.patients with ECOG performance status 3 and 4 4.pregnant women and lactating mothers

Design outcomes

Primary

MeasureTime frame
AIM To evaluate clinical outcome variations and dose volumetric changes with adaptive IMRT in head and neck cancers objectives to document and assess following parameters 1. acute toxicities a) mucositis b) dermatitis c) dysphagia d) voice changes e) xerostomia 2. clinical responce rate a) changes in gross tumor volume (GTV) b) changes in nodal volume 3. Dose volumetric parameters a) dose to parotid gland b) dose to spinal cordTimepoint: all the patients will undergo CT simulation and treatment planning by IMRT patients will be assessed baseline and weekly basis during RT for acute toxicities patients will undergo rescan and replanning around 23fractions (3 to 5 weeks) and dose volume changes are compared with inital scan—

Countries

India

Contacts

Public ContactDr Pranabandhu Das

Sri venkateswara institute of medical sciences

daspranabandhu@gmail.com9493547731

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026